Table 1.

Summary of patient characteristics.

	All HF patients (n=23)	non-CKD HF (n=11)	CKD HF (n=12)	p-value
Age (years±SD)	67±12	61±11	72±11	0.027
Male/Female	12/11	6/5	6/6	0.827
Cardiovascular Risk Factors
Smoking	5 (22%)	4 (36%)	1 (8%)	0.103
Diabetes mellitus	11 (47%)	4 (36%)	7 (58%)	0.292
Arterial Hypertension	16 (70%)	7 (64%)	9 (75%)	0.554
Hyperlipidemia	13 (56%)	6 (55%)	7 (58%)	0.855
Obesity	8 (35%)	4 (36%)	4 (33%)	0.879
BMI	27.7±7.8	27.1±7.4	28.3±8.6	0.898
HF Characteristics
ICM HFrEF	16 (70%)	7 (64%)	9 (75%)	0.554
Non-ICM HFrEF	7 (30%)	4 (36%)	3 (25%)	0.554
NYHA I	0	0	0
NYHA II	13 (57%)	6 (55%)	7 (58%)	0.855
NYHA III	10 (43%)	5 (45%)	5 (42%)	0.855
NYHA IV	0	0	0
Kidney Function
S-Creatinin (mg/dl)	1.61	0.99	2.18	<0.0001
eGFR (ml/min/m2)	50	75	28.2	<0.0001
Cystatin C (mg/l)	1.85±0.7	1.15±0.42	2.49±0.48	<0.0001
Iron Metabolism
Ferritin (μg/l)	67±48	77±53	59±42	0.525
Transferrin (g/l)	297±47	303±30	291±59	0.786
Iron (μmol/l)	64±33	77±40	51±21	0.069
Soluble transferrin receptor (mg/l)	5.6±3.3	3.8±1.9	7.2±3.4	0.008
Transferrin saturation (%)	15.8±8.7	18.8±10.4	13±6	0.138
Inflammation and Others
hsCRP (mg/l)	6.8±6.1	5,3±6.3	8.1±6.9	0.275
IL6 (mg/dl)	15.9±12.1	16.9±15.4	15.2±10.3	0.976
NT-proBNP (ng/l)	3947±2219	4927±2816	4459±3210	0.048
AST (U/l)	29.3±13.2	34.6±14.5	24.4±10.1	0.100
HF Medication
ACE-I/ARB	16 (70%)	7 (64%)	9 (75%)	0.554
ARNI	6 (26%)	3 (27%)	2 (17%)	0.538
β-blockers	22 (96%)	11 (100%)	11 (91%)	0.328
MRA	11 (48%)	6 (55%)	5 (42%)	0.879
Diuretic	23 (100%)	11 (100%)	12 (100%)	0.999
Statin	16 (70%)	7 (64%)	9 (75%)	0.554